← Back to Search

Macrolide Antibiotic

Hydroxychloroquine for Coronavirus (HyAzOUT Trial)

Phase 3
Waitlist Available
Led By Brandon Webb, MD
Research Sponsored by Intermountain Health Care, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from enrollment to 14 days after enrollment
Awards & highlights

HyAzOUT Trial Summary

This trial will compare hydroxychloroquine to azithromycin in treating COVID-19.

Eligible Conditions
  • Coronavirus
  • COVID-19

HyAzOUT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from enrollment to 14 days after enrollment
This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrollment to 14 days after enrollment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Hospitalization within 14 days of enrollment
Secondary outcome measures
Duration of COVID-19-attributable symptoms
Hospital-free days at 28 days
ICU-free days at 28 days
+1 more

Side effects data

From 2016 Phase 3 trial • 217 Patients • NCT02057250
13%
Upper respiratory tract infection
6%
Neutropenia
6%
Sinusitis
5%
Alanine aminotransferase increased
5%
Urinary tract infection
4%
Injection site erythema
4%
Accidental overdose
4%
Bronchitis
3%
Injection site pruritus
2%
Thrombocytopenia
2%
Nasopharyngitis
2%
Contusion
1%
Arthralgia
1%
Anaemia
1%
Lumbar spinal stenosis
1%
Leukopenia
1%
Coronary artery occlusion
1%
Wolff-Parkinson-White syndrome
1%
Transient ischaemic attack
1%
Vertebrobasilar insufficiency
1%
Chronic obstructive pulmonary disease
1%
Small intestinal obstruction
1%
Nephrolithiasis
1%
Cataract
1%
Thrombophlebitis superficial
1%
Vomiting
1%
Endometrial hyperplasia
1%
Traumatic arthritis
1%
Hypertension
1%
Pneumonia
1%
Pancreatic carcinoma metastatic
1%
Osteoarthritis
1%
Rheumatoid lung
1%
Pharyngitis
1%
Femoral neck fracture
100%
80%
60%
40%
20%
0%
Study treatment Arm
Sarilumab 150 mg by PFS (Extension Phase)
Sarilumab 150 mg by AID (AID Assessment Phase)
Sarilumab 150 mg by PFS (AID Assessment Phase)
Sarilumab 200 mg by PFS (AID Assessment Phase)
Sarilumab 200 mg by AID (AID Assessment Phase)

HyAzOUT Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: HydroxychloroquineExperimental Treatment1 Intervention
Group II: AzithromycinActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Hydroxychloroquine
FDA approved

Find a Location

Who is running the clinical trial?

Intermountain Health Care, Inc.Lead Sponsor
137 Previous Clinical Trials
1,961,560 Total Patients Enrolled
Utah Department of HealthOTHER
6 Previous Clinical Trials
478,571 Total Patients Enrolled
University of UtahOTHER
1,099 Previous Clinical Trials
1,777,139 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19
Brandon Webb 2020. "Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04334382.
All > Covid
~310 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top